Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degeneration

Pharmaceutical Development and Technology

Volumn 21, Issue 1, 2016, Pages 61-67

  Hirani, Anjali ^a,b   Grover, Aditya ^a   Lee, Yong W ^b   Pathak, Yashwant ^a   Sutariya, Vijaykumar ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Age related macular degeneration; PLGA nanoparticles; thermoreversible gel; triamcinolone acetonide; VEGF

Indexed keywords

NANOPARTICLE; POLYGLACTIN; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; GEL; MACROGOL DERIVATIVE; POLY(LACTIC-CO-GLYCOLIC ACID)-POLYETHYLENE GLYCOL-POLY(LACTIC-CO-GLYCOLIC ACID); VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; GEL; GELATION; IN VITRO STUDY; INTRACELLULAR TRANSPORT; NANOENCAPSULATION; PARTICLE SIZE; PHASE TRANSITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUSTAINED DRUG RELEASE; THERMOREVERSIBLE GEL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MACULAR DEGENERATION; METABOLISM; PROCEDURES; RETINAL PIGMENT EPITHELIUM; TEMPERATURE;

CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; GELS; HUMANS; MACULAR DEGENERATION; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; RETINAL PIGMENT EPITHELIUM; TEMPERATURE; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84955064948     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2014.965326     Document Type: Article

References (48)

1. Gopal L, Sharma T. Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration. Ind J Ophthalmol 2007; 55: 431-435
2. Sherif Z, Pleyer U. Corticosteroids in ophthalmology: past-present-future. Ophthalmologica 2002; 216: 305-315
3. Wu WS, Wang FS, Yang KD, et al. Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. J Investig Dermatol 2006; 126: 1264-1271
4. Wang YS, Friedrichs U, Eichler W, et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefe's archive for clinical and experimental Ophthalmology 2002; 240: 42-48
5. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-Treated rat model. Arch Ophthalmol 2001; 119: 399-404
6. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110: 1517-1525
7. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids. Drug Safety 2002; 25: 33-55
8. Fernández-Robredo P, Sancho A, Johnen S, et al. Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering. J Ophthalmol 2014; 2014: Article ID:510285
9. Prevalence of Adult Vision Impairment and Age-Related Eye Diseases in America. Available from: http://www.nei.nih.gov/eyedata/adultvision-usa.asp2010
10. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006; 58: 353-363
11. Regatieri C, Dreyfuss J, Nader H. Experimental treatments for neovascular age-related macular degeneration. In: Ying G-S., ed. Age related macular degeneration-The recent advances in basic research and clinical care. Rijeka, Croatia: InTech; 2012: 83-98
12. Buschini E, Piras A, Nuzzi R, Vercelli A. Age related macular degeneration and drusen: neuroinflammation in the retina. Prog Neurobiol 2011; 95: 14-25
13. Bylsma GW, Guymer RH. Treatment of age-related macular degeneration. ClinExp Optomet 2005; 88: 322-334
14. Thrimawithana T, Young S, R Bunt C, et al. Drug delivery to the posterior segment of the eye: challenges and opportunities. Drug Deliv Lett 2011; 1: 40-44
15. Park YG, Rhu HW, Kang S, Roh YJ. New approach of anti-VEGF agents for age-related macular degeneration. J Ophthalmol 2012; 2012: Article ID:637316
16. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676
17. Group MPS. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 1993; 111: 1200-1209
18. Zhang W, Prausnitz MR, Edwards A. Model of transient drug diffusion across cornea. J Control Release 2004; 99: 241-258
19. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58: 1131-1135
20. Gambhire S, Bhalerao K, Singh S. In situ hydrogel: different approaches to ocular drug delivery. Int J Pharm Pharm Sci 2013; 5 (2): 27-36
21. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina 2009; 29: 875-912
22. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010; 12: 348-360
23. Zhou HY, Hao JL, Wang S, et al. Nanoparticles in the ocular drug delivery. Int J Ophthalmol 2013; 6: 390-396
24. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol 2013; 2: 47-64
25. Sabzevari A, Adibkia K, Hashemi H, et al. Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: In vitro and in vivo studies. Eur J Pharm Biopharm 2013; 84: 63-71
26. Bu H-Z, Gukasyan HJ, Goulet L, et al. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab 2007; 8: 91-107
27. Bourges J-L, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Investig Ophthalmol Vis Sci 2003; 44: 3562-3569
28. Bala I, Hariharan S, Kumar MR. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004; 21: 387-422
29. Geldenhuys W, Mbimba T, Bui T, et al. Brain-Targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target 2011; 19: 837-845
30. Carroll RT, Bhatia D, Geldenhuys W, et al. Brain-Targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target 2010; 18: 665-674
31. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008; 16: 16-29
32. Li F, Hurley B, Liu Y, et al. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J 2012; 6: 50-58
33. Nirmal H, Bakliwal S, Pawar S. In-situ gel: new trends in controlled and sustained drug delivery system. Int J PharmTech Res 2010; 2: 1398-1408
34. Choi BG, Park MH, Cho S-H, et al. In situ thermal gelling polypeptide for chondrocytes 3D culture. Biomaterials 2010; 31: 9266-9272
35. Park D, Shah V, Rauck BM, et al. An anti-Angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration. Macromol Biosci 2013; 13: 464-469
36. Vodithala S, Khatry S, Shastri N, Sadanandam M. Development and evaluation of thermoreversible ocular gels of ketorolac tromethamine. Int J Biopharm 2010; 1: 39-45
37. Sutariya V, Miladore N, Geldenhuys W, et al. Thermoreversible gel for delivery of activin receptor-like kinase 5 inhibitor SB-505124 for glaucoma filtration surgery. Pharm Dev Technol 2013; 18: 957-962
38. Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech 2006; 7: E80-E86
39. Duvvuri S, Janoria KG, Mitra AK. Development of a novel formulation containing poly (d, l -lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir. J Control Release 2005; 108: 282-293
40. Moghimipour E, Tafaghodi M, Balouchi A, Handali S. Formulation and in vitro evaluation of topical liposomal gel of triamcinolone acetonide. Res J Pharma Biol Chem Sci. 2013; 4: 101-107
41. Gómez-Gaete C, Tsapis N, Besnard M, et al. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm 2007; 331: 153-159
42. Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm 2007; 336: 367-375
43. Patel SP, Vaishya R, Mishra GP, et al. Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics. J Drug Deliv 2014; 2014: Article ID: 401747. doi: 10.1155/2014/401747
44. Tamboli V, Mishra GP, Mitra AK. Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles. Colloid Polym Sci 2013; 291: 1235-1245
45. Suen WL, Chau Y. Specific uptake of folate-decorated triamcinolone-encapsulating nanoparticles by retinal pigment epithelium cells enhances and prolongs antiangiogenic activity. J Control Release 2013; 167: 21-28
46. Yoncheva K, Lambov N. Development of biodegradable poly (alpha-methylmalate) microspheres. Die Pharmazie 2000; 55: 148-150
47. Yasukawa T, Ogura Y, Tabata Y, et al. Drug delivery systems for vitreoretinal diseases. Progr Retinal Eye Res 2004; 23: 253-281
48. Kadam RS, Tyagi P, Edelhauser HF, Kompella UB. Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm 2012; 434: 140-147